Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    StockNews24StockNews24
    Subscribe
    • Shares
    • News
      • Featured Company
      • News Overview
        • Company news
        • Expert Columns
        • Germany
        • USA
        • Price movements
        • Default values
        • Small caps
        • Business
      • News Search
        • Stock News
        • CFD News
        • Foreign exchange news
        • ETF News
        • Money, Career & Lifestyle News
      • Index News
        • DAX News
        • MDAX News
        • TecDAX News
        • Dow Jones News
        • Eurostoxx News
        • NASDAQ News
        • ATX News
        • S&P 500 News
      • Other Topics
        • Private Finance News
        • Commodity News
        • Certificate News
        • Interest rate news
        • SMI News
        • Nikkei 225 News1
    • Carbon Markets
    • Raw materials
    • Funds
    • Bonds
    • Currency
    • Crypto
    • English
      • العربية
      • 简体中文
      • Nederlands
      • English
      • Français
      • Deutsch
      • Italiano
      • Português
      • Русский
      • Español
    StockNews24StockNews24
    Home » Up 7.5% in a week! Is the GSK share price about to do an AstraZeneca?
    News

    Up 7.5% in a week! Is the GSK share price about to do an AstraZeneca?

    userBy userMay 1, 2025No Comments3 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    When I first started writing for The Motley Fool more than two decades ago, the GSK (LSE: GSK) share price was a FTSE 100 shining light.

    In my recollection, GlaxoSmithKline, as it was known then, even outshone pharmaceutical sector rival AstraZeneca (LSE: AZN). It’s a different story today.

    A tale of two pharma stocks

    Since taking the helm in October 2012, CEO Pascal Soriot has transformed AstraZeneca into the UK’s biggest company. Last summer, its market-cap topped £200bn. Although today it’s down to £166bn.

    Since the start of the Millennium in January 2000, AstraZeneca’s share price has soared from 2,395p to 10,775p, an impressive increase of around 350%. And that’s before accounting for dividends.

    By contrast, GSK’s journey has been more turbulent. From a high of 1,767p in January 2000, its share price has dipped to 1,482p today. While dividends have cushioned the blow, it’s a stark comparison to AstraZeneca’s meteoric rise.​

    GSK’s dividend, once seen as a stellar source of income with a typical yield of between 5% and 6%, isn’t what it was. It was frozen at 80p from 2014 to 2021, as CEO Emma Walmsley diverted shareholder cash into R&D, in a bid to replenish the group’s ailing drugs pipeline.

    Dividends have slipped

    It was then reduced to 57.75p in 2022 following the Haleon spin-off. In 2024, it edged up to 61p, offering a yield of 4.1%.​

    Now there’s a glimmer of hope. GSK’s recent Q1 2025 results, published on 30 April, reignited investor interest, pushing the share price up by 7.5% over the past week. Although it’s still down 11% over 12 months.

    The company reported sales of £7.52bn, a 4% increase year-on-year. Specialty Medicines were the standout, with sales up 17%, including a 28% rise in Respiratory, Immunology, and Inflammation, and a 53% surge in Oncology. 

    Operating profit jumped 50%, while cash generated from operations exceeded £1bn, with free cash flow of £700m.

    GSK expects to pay a full-year dividend of 64p per share, up almost 5%, and announced a £2bn share buyback, with £273m repurchased in Q1. 

    The company also reaffirmed its full-year guidance, anticipating 3-5% turnover growth and a 6-8% rise in core EPS.

    Different stocks, different values

    AstraZeneca’s Q1 results, released a day earlier, showed a 10% increase in total revenue to $13.6bn and a 21% rise in core EPS to $2.49. Market reaction was muted, perhaps due to the high expectations set by its recent performance. The AstraZeneca share price is up 3.5% in a week, but like GSK, is down 11% over 12 months.

    I don’t hold AstraZeneca shares. Last year, I deemed them too pricey. Instead, I placed my bets on GSK, viewing it as an undervalued opportunity. 

    So far, that decision has left me about 20% down, not helped by concerns over potential US tariffs on pharmaceutical imports. Walmsley believes the company can navigate these challenges through AI integration and supply chain adjustments. We’ll see.

    As a contrarian investor, I’m inclined to stick with GSK. There’s potentially more value here, with a price-to-earnings ratio of just over eight, less than half AstraZeneca’s P/E of 17. The recent uptick is encouraging, but there’s still a long road ahead. I’m hoping Walmsley’s masterplan will start paying off, but despite the recent jump, I suspect there’s a long way to go. 



    Source link

    Share this:

    • Click to share on Facebook (Opens in new window) Facebook
    • Click to share on X (Opens in new window) X

    Like this:

    Like Loading...

    Related

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleI think this could be the best investment opportunity on the FTSE 100
    Next Article Up 703%, could Rolls-Royce shares crash?
    user
    • Website

    Related Posts

    3 reasons to like Apple stock

    May 24, 2025

    This FTSE 250 stock just fell 20% in a week — what should investors do?

    May 24, 2025

    Investing £20k in this Stocks and Shares ISA each year since 2020 is now worth…

    May 24, 2025
    Add A Comment

    Leave a ReplyCancel reply

    © 2025 StockNews24. Designed by Sujon.

    Type above and press Enter to search. Press Esc to cancel.

    %d